Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Myung Ah | - |
dc.contributor.author | Cho, Eun Kyung | - |
dc.contributor.author | Oh, Sung Yong | - |
dc.contributor.author | Ahn, Joong Bae | - |
dc.contributor.author | Lee, Ji Yun | - |
dc.contributor.author | Burke, Thomas | - |
dc.contributor.author | Jung, Hun | - |
dc.contributor.author | Kim, Jong Gwang | - |
dc.date.available | 2020-02-28T00:43:07Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2016-10 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/7842 | - |
dc.description.abstract | Purpose This study reported patient outcomes of chemotherapy-induced nausea and vomiting (CINV) prophylaxis for highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) regimens and evaluated its adherence to acute-phase CINV prophylaxis in the Korean population subset of the Pan Australasian Chemotherapy Induced Emesis burden of illness (PrACTICE) study. Materials and Methods This subgroup analysis evaluated 158 Korean patients receiving HEC or MEC and compared the data (wherever possible) with that of 648 patients from the Asia-Pacific (AP) region. Study endpoints included evaluation of primary CINV prophylaxis and adherence to acute phase CINV prophylaxis in cycle 1 (American Society of Clinical Oncology [ASCO] Quality Oncology Practice Initiative [QOPI]). Results In South Korea and the AP, a 5-hydroxytrypta mine-3 receptor antagonist (5HT(3)-RA) prophylaxis for the acute phase was administered to 79/80 patients (98.8%) for HEC and 70/71 patients (98.6%) for MEC regimens (QOPI-1). Triple regimen (corticosteroid-5HT(3)-RA-neurokinin 1-RA) was initiated in 46/80 patients (57.5%) for prophylaxis of acute CINV in cycle 1 of HEC (QOPI-3). Double regimen (corticosteroid-5HT(3)-RA, with or within NK1-RA) was initiated in 61/71 patients (83.1%) for control of acute CINV in cycle 1 of MEC a(QOPI-2). Conclusion Active management of CINV is necessary in cycle 1 of HEC in South Korea, despite higher rates than the AP region. Adherence to the international guidelines for CINV prophylaxis requires attention in the acute phase in cycle 1 of the HEC regimen. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.subject | HIGHLY EMETOGENIC CHEMOTHERAPY | - |
dc.subject | ANTIEMETIC GUIDELINES | - |
dc.subject | RECEIVING CHEMOTHERAPY | - |
dc.subject | CINV | - |
dc.subject | ADHERENCE | - |
dc.subject | IMPROVEMENT | - |
dc.subject | COUNTRIES | - |
dc.subject | PATTERNS | - |
dc.subject | NURSES | - |
dc.subject | MASCC | - |
dc.title | Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000385212800027 | - |
dc.identifier.doi | 10.4143/crt.2015.309 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.48, no.4, pp.1420 - 1428 | - |
dc.identifier.kciid | ART002154935 | - |
dc.identifier.scopusid | 2-s2.0-84996636575 | - |
dc.citation.endPage | 1428 | - |
dc.citation.startPage | 1420 | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 48 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Cho, Eun Kyung | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Nausea | - |
dc.subject.keywordAuthor | Vomiting | - |
dc.subject.keywordAuthor | Drug therapy | - |
dc.subject.keywordAuthor | Antiemetics | - |
dc.subject.keywordPlus | HIGHLY EMETOGENIC CHEMOTHERAPY | - |
dc.subject.keywordPlus | ANTIEMETIC GUIDELINES | - |
dc.subject.keywordPlus | RECEIVING CHEMOTHERAPY | - |
dc.subject.keywordPlus | CINV | - |
dc.subject.keywordPlus | ADHERENCE | - |
dc.subject.keywordPlus | IMPROVEMENT | - |
dc.subject.keywordPlus | COUNTRIES | - |
dc.subject.keywordPlus | PATTERNS | - |
dc.subject.keywordPlus | NURSES | - |
dc.subject.keywordPlus | MASCC | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.